ASCO 2026: Breakthrough in Metastatic Uveal Melanoma

Primary results from the global OptimUM-02 Phase II/III clinical trial, presented at the ASCO Annual Meeting 2026 (May 29 - June 2), revealed promising outcomes for darovasertib combined with Xalkori. This combination was evaluated as a first-line therapy for patients with HLA A*02:01-negative metastatic uveal melanoma.

The trial met its primary efficacy endpoint, demonstrating a median progression-free survival of 6.9 months for the darovasertib-Xalkori arm compared to 3.1 months for investigator's choice therapy. This represents a 58% reduction in the risk of progression or death. The objective response rate was a notable 37.1% with the combination, significantly higher than the 5.8% observed in the control group.

Regarding safety, while nearly all patients experienced treatment-related adverse events, serious adverse events were lower with darovasertib plus Xalkori (9.2%) compared to investigator's choice therapy (25.0%). Discontinuations due to adverse events were also reduced. These findings support darovasertib and Xalkori as a potential new standard of care for this patient population.

Currently, there are no direct competitors for first-line HLA A*02:01 negative metastatic UM. While Immunocore's Kimmtrak is approved, it is restricted to HLA A*02:01-positive patients. DelcathSystems' Hepzato offers a complementary liver-directed therapy. Replimune's sturlimogene erparepvec in combination with Opdivo is in development, representing the closest pipeline challenger.

Global sales for darovasertib are projected to reach $709 million by 2032, with a planned New Drug Application submission in the second half of 2026. Commercialization efforts will span US and international markets, although expansion into earlier treatment settings may be necessary for sustained long-term revenue growth given the niche uveal melanoma market.